using opioids, 44% used short-acting, 19% long-acting, and 37% both. Prevalence of OpA among those with a history of opioid use was 0.56% compared to 0.06% in non-users (pϽ0.0001). All HCRU was significantly greater for the pre-index and post-index periods for OpAers compared to controls (pϽ0.0001). Total health care costs were greater for OpAers compared with controls; $11,137Ϯ26,677 versus $2,231Ϯ8,438 (pϽ0.0001) in the pre-index and $25,654Ϯ54,928 vs. $4,902Ϯ18,682 (pϽ0.0001) in the post-index periods, respectively. Prescription opioid costs for OpAers and controls was $1,935Ϯ6844 and $34Ϯ486 (pϽ0.0001), respectively. Among OpAers, total healthcare costs were greater for those with pre-index opioid use compared with those without pre-index opioid use; $13,920Ϯ30,012 versus $5,222Ϯ16,073 (pϽ0.0001) in the pre-index and $29, 500Ϯ56,713 versus $17,481Ϯ49,960 (pϽ0.0001) in the post-index periods. CONCLUSIONS: OpAers have significantly greater HCRU and total cost before and after OpA compared to matched controls. OpAers with opioid use had significantly greater total cost before and after OpA than OpAers without opioid use. 53 (3.13-3.94) for PM, and 0.73 (0.66-0.81) and 0.78 (0.58-0.97) for interstitial myositis for the commercial/Medicare and Medicaid cohorts respectively. Annual incidence fluctuated over time with the base MarketScan populations. There were 7,155 prevalent patients, with annual prevalence ranging from 20.62 to 25.32 per 100,000 for commercial/Medicare (83% of prevalent cases) and from 15.35 to 32.74 for Medicaid. Sensitivity analysis reduced the incidence rates and prevalence by 20-40%. CONCLUSIONS: This study found higher IIM incidence and prevalence than historical small population based reports. Employer turnover, miscoding and misdiagnosing, care seeking behavior, and fluctuations in database membership over time can influence the results. Further studies are needed to confirm the incidence and prevalence of IIMs in the US population.
OBJECTIVES:
Modifiable risk factors in the US workforce have been documented previously, but knowledge of behavioral risk factor prevalence among working adults remains incomplete. To assess current national estimates for smoking, heavier alcohol consumption, obesity, insufficient exercise and fair/poor health status for working adults aged 20 years and older. METHODS: Analysis of nationally representative data collected from employed adults 20 years and older participating in the National Health Interview Survey (NHIS) 2010 (aged 20 to 64 years, n ϭ 13,844, aged 20 to 39 years, nϭ6,495, aged 40 to 64 years, nϭ7,349, men aged 20 to 64 years ϭ 6,825, women aged 20 to 64 years ϭ 7,019). RESULTS: The prevalence of current smoking among working adults aged 20 to 64 years is 19.6%; younger workers (aged 20 to 39 years) have a significantly higher prevalence of current smoking than workers 40 to 64 years, (21.2% vs. 18.3%, pϭ0.001) and employed men have a significantly higher smoking prevalence than employed women (21.4% vs. 17.6%, respectively, pϭϽ0.0001). An estimated 5.7% and 5.5% of working men and women, respectively, report heavier alcohol consumption (pϭ0.5573, Ͼ2 drinks/day for men, Ͼ1 drink/day for women). The prevalence of insufficient exercise is equivalent among working men and women, 30.6% and 31.0%, respectively. Obesity prevalence in the workforce is 33.5%; obesity rates are 31.6% and 35.1% among workers 20 to 39 years and 40 to 64 years, respectively (pϭ0.2665). Employed women and men are equally likely to report that their health is fair/poor (6.0% vs. 5.1%). CONCLUSIONS: Current smoking, insufficient exercise and obesity are prevalent in the US workforce. Effective workplace approaches including increased dissemination of educational information are needed to reduce the burden of these risk factors. 
SYSTEMIC DISORDERS/CONDITIONS -Cost

OBJECTIVES:
Tapentadol ER is a new oral analgesic that has been shown to have a lower incidence of gastrointestinal adverse events (AEs) than oxycodone CR at equianalgesic doses. We estimated the annual budget impact of placing tapentadol ER on a health plan formulary of long-acting opioids (LAOs) used to treat moderate to severe chronic pain. METHODS: An Excel-based budget impact model was developed to estimate the annual direct healthcare costs associated with long-acting formulations of tapentadol, oxycodone, morphine, hydromorphone, oxymorphone, and fentanyl. Costs included medications, copayments, AE management and opioid switching/discontinuation. Incidence/prevalence estimates, AEs and pain management resources and costs (medications, physician phone calls, office visits, emergency room visits and hospitalizations) were based on published sources. Drug costs were based on wholesale acquisition cost. All costs were in 2010 US dollars. Weighted-average daily drug consumption (DACON) and formulary share were obtained from IMS Health. Base case analysis assumed a 10% formulary share of tapentadol ER with a 10% decrease of oxycodone CR. Results are presented as the per-member per-month (PMPM) cost difference after adding tapentadol ER to the formulary. RESULTS: In a health plan of 500,000 members, 2,600 (0.52%) would be expected to experience chronic pain annually and be treated with an LAO for an average of 180 days. Adding tapentadol ER to the formulary (10% share) decreased both pharmacy (-$0.0136 PMPM) and medical (-$0.0008 PMPM) costs as well as total costs (-$0.0144 PMPM), with annual budget savings of $85,992. This was driven by lower DACON and lower incidence of AEs with tapentadol ER versus oxycodone CR, leading to reduced resource use and costs. In sensitivity analysis, results were most sensitive to drug acquisition costs. CONCLUSIONS: Results suggest that increasing market share of tapentadol ER while reducing oxycodone CR would decrease a health plan's budget by decreasing both pharmacy and medical costs. 
PSY13 EFFECT OF RISK-SHARE AGREEMENTS ON BUDGET IMPACT: A CASE STUDY OF CERTOLIZUMAB PEGOL IN THE TREATMENT OF RHEUMATOID ARTHRITIS
OBJECTIVES:
Illustrate potential budgetary impact of a risk-share agreement in a US health plan using a case study of certolizumab pegol (CZP) as treatment for moderate to severe rheumatoid arthritis (RA). METHODS: An economic model was developed to evaluate the budget impact to a hypothetical 50 million member health plan of adding CZP to a formulary. The target population was patients naïve to TNF inhibitors. Model comparators included adalimumab, etanercept, infliximab, and golimumab. Comparable efficacy is assumed across therapies; discontinuation rates were assumed to differ by therapy, as evidenced by claims data. Model parameters were estimated using published data, market research, and an administrative claims database analysis. The base-case included a risk-share component for which the health plan received a rebate for clinically non-responsive CZP patients at week 12. Non-responsive CZP patients were assumed to receive an alternative TNF-alpha inhibitor for the remainder of the 3-year model horizon. Analyses captured differences in drug acquisition and intravenous administration costs for the base-case and an alternate scenario assuming no risk-share agreement. Deterministic sensitivity analyses were also conducted. RESULTS: Assuming a risk-share agreement, per-patient per-month (PPPM) savings in years 1, 2, and 3 were $4.22, $2.26, and $2.26, respectively. Applied to a hypothetical health-plan of 50 million members, annual cost savings are $3.6M, $2M, and $2.1M in years 1, 2, and 3, respectively. Without a risk-share agreement, PPPM savings were $3.27 in year 1 and $2.21 in years 2 and 3. Model results were most sensitive to average monthly pharmacy costs of CZP and infliximab. CONCLUSIONS: The analysis suggests that under a risk-share agreement, the addition of CZP to a US health plan formulary may result in cost savings to the plan. Additionally, even without a risk-share agreement, the addition of CZP may provide cost savings. 
PSY14 HEALTH CARE COSTS AND OPIOID USE AMONG PATIENTS WITH CHRONIC LOW BACK PAIN INITIATING DULOXETINE VERSUS OTHER TREATMENTS
OBJECTIVES:
This study aimed to compare direct healthcare costs and opioid use over a 1-year period following initiation with duloxetine versus other standard of care (SOC) treatments among patients with chronic low back pain (CLBP). METHODS: This retrospective cohort study assessed commercially-insured Marketscan CLBP patients aged 18-64 years who initiated duloxetine or other treatments (tricyclic antidepressants, venlafaxine, pregabalin, gabapentin, muscle relaxants and opioids) in 2009. The first dispense date was defined as the index date. Selected patients were required to have at least two low back pain (LBP) inpatient or outpatient claims with at least 90 days gap between the 2 in the 12-month preindex period. Both duloxetine and SOC cohorts were then matched via propensity scoring (nϭ668 for each cohort), controlling for demographics, comorbidities, prior healthcare utilization and costs, and prior medication history. Health care costs and opioid use (among patients not initiated on opioids) over the 12-month postindex period were compared between cohorts. RESULTS: Total health care costs over the 12-month post-index period were $17,435 among duloxetine-initiated patients, versus $19,633 (pϭ0.1781) for SOC-initiated patients. Duloxetine-initiated patients also had significantly lower inpatient costs ($3,486 vs. $5,975, pϭ0.0219). While both groups had similar outpatient costs ($9,558 vs. $10,424, pϭ0.3324), CLBP-related outpatient costs were significantly lower among duloxetine-initiated A100 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) A 1 -A 2 5 6
